Valuation: Formycon AG

Capitalization 330M 385M 302M 287M 529M 37.05B 538M 3.62B 1.4B 17.53B 1.44B 1.41B 61.11B P/E ratio 2026 *
-17.8x
P/E ratio 2027 * 9.6x
Enterprise value 404M 471M 370M 351M 647M 45.35B 658M 4.43B 1.72B 21.46B 1.77B 1.73B 74.79B EV / Sales 2026 *
6.66x
EV / Sales 2027 * 2.93x
Free-Float
70%
Yield 2026 *
-
Yield 2027 * -
1 day-0.95%
1 week-1.89%
Current month+3.31%
1 month-5.65%
3 months-20.93%
6 months-16.33%
Current year-26.95%
1 week 18.36
Extreme 18.36
19.6
1 month 17.5
Extreme 17.5
20.1
Current year 15.8
Extreme 15.8
26.95
1 year 15.8
Extreme 15.8
31.3
3 years 15.8
Extreme 15.8
79.5
5 years 15.8
Extreme 15.8
94.1
10 years 14.65
Extreme 14.65
94.1
Manager TitleAgeSince
Chief Executive Officer - 01/07/2022
Director of Finance/CFO 57 01/04/2023
Chief Tech/Sci/R&D Officer - 01/07/2022
Director TitleAgeSince
Director/Board Member 49 10/12/2020
Chairman 54 12/06/2024
Director/Board Member 54 12/06/2024
Change 5d. change 1-year change 3-years change Capi.($)
-0.95%-1.89%-18.34%-75.90% 388M
-0.23%-2.80%-18.36%-17.20% 41.67B
-0.06%-5.68%+28.33%+28.14% 32.6B
-0.89%+0.15%+265.12%+468.83% 30.97B
+2.18%-0.43%+21.00%-11.58% 28.23B
-2.97%-4.23%+23.72%+16.24% 26.41B
-1.19%-0.43% - - 14.94B
-2.76%+1.68%+168.71%+4,393.86% 14.13B
-2.30%-3.79%+116.09%+97.98% 12.27B
+1.35%+2.67%+7.06%-0.17% 12.12B
Average -0.78%-1.20%+65.93%+544.47% 21.37B
Weighted average by Cap. -0.58%-1.63%+67.79%+392.82%

Financials

2026 *2027 *
Net sales 60.76M 70.71M 55.59M 52.79M 97.21M 6.81B 98.87M 665M 258M 3.22B 265M 260M 11.23B 131M 153M 120M 114M 210M 14.72B 214M 1.44B 557M 6.96B 573M 561M 24.27B
Net income -18.59M -21.63M -17.01M -16.15M -29.74M -2.08B -30.24M -204M -78.89M -986M -81.19M -79.47M -3.44B 34.21M 39.81M 31.3M 29.72M 54.73M 3.84B 55.66M 375M 145M 1.81B 149M 146M 6.33B
Net Debt 73.99M 86.12M 67.7M 64.3M 118M 8.3B 120M 810M 314M 3.93B 323M 316M 13.68B 54.52M 63.46M 49.89M 47.38M 87.24M 6.11B 88.72M 597M 231M 2.89B 238M 233M 10.08B
Logo Formycon AG
Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.
Employees
250
Date Price Change Volume
18/05/26 18.70 -0.95% 9,726
15/05/26 18.88 -0.63% 6,428
14/05/26 19.00 -0.84% 4,065
13/05/26 19.16 +4.70% 11,778
12/05/26 18.30 -3.99% 5,695
Trader
Investor
Global
Quality
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
18.70EUR
Average target price
40.14EUR
Spread / Average Target
+114.67%

Quarterly revenue - Rate of surprise